Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVAS-an interesting california-based biotech company here -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (103)	9/29/2002 8:47:55 PM
From: mopgcw	Read Replies (1) \| Respond to of 126

Biotech Value Fund Ups Corvas Stake To 19.4% From 17.7% DOW JONES NEWSWIRES WASHINGTON -- A group including Biotechnology Value Fund LP increased its stake in Corvas International Inc. (CVAS) to 19.4%, according to an amended Schedule 13D filed Friday with the Securities and Exchange Commission. The group beneficially owns 5,341,029 common shares. It purchased 406,800 shares between July 25 and Sept. 12 for prices from $1.25 to about $1.46 a share. On Sept. 16, the group reported a 17.7% stake in Corvas, a San Diego-based clinical-stage biopharmaceutical company.